Earnings call transcript: Elliptic Labs Q3 2025 sees 50% revenue growth

Vivendi's stock has experienced a decline as the potential for a takeover weakens following a legal opinion. This negative sentiment reflects investor concerns about the company's future prospects and market position.

Structure Therapeutics has had its stock rating reiterated ahead of the release of key trial data. This decision reflects the company's ongoing evaluation of its market position and investor sentiment as it prepares for significant developments in its clinical trials.

Jefferies has lowered its stock price target for ZTO Express to $25, reflecting a negative outlook on the market. This adjustment comes amid concerns regarding the company's financial performance and broader market conditions. Investors are reacting to these developments with caution as they assess the implications for ZTO Express's growth potential.

Mizuho has raised the stock price target for Block from $88 to $100 following a positive analyst day. This adjustment reflects the firm's confidence in Block's future performance and aligns with the overall positive sentiment in the market.

TD Cowen has reiterated a Buy rating for Block stock, maintaining a price target of $91. This affirmation comes amid positive market sentiment, indicating confidence in Block's future performance. The recommendation suggests that investors may find value in Block shares as the market outlook remains optimistic.

BMO Capital has reiterated its stock rating for Samsara as 'Outperform'. This decision reflects the firm's confidence in Samsara's market position and potential for growth. The rating is part of BMO Capital's ongoing analysis of market trends and company performance.

SW Finance has successfully completed a tender offer for £226 million of bonds, marking a significant financial maneuver aimed at optimizing its capital structure. This move is expected to enhance the company's financial flexibility and support its growth initiatives.

VNET DRC reported earnings that fell short of analysts' expectations by ¥1.23, although its revenue exceeded estimates. This negative performance highlights ongoing challenges for the company in meeting profitability targets, raising concerns among investors regarding its financial health.